Altintas Ayse Gul Kocak, Ilhan Cagri
Ankara Ulucanlar Eye Education and Research Hospital, University of Health Sciences, Ankara, Turkey.
Hatay Education and Research Hospital, Hatay Turkey.
Arq Bras Oftalmol. 2023 Jan-Feb;86(1):13-19. doi: 10.5935/0004-2749.20230011.
To investigate the effects of epiretinal membrane formation on the clinical outcomes of intravitreal dexamethasone implantation for macular edema secondary to branch retinal vein occlusion.
This retrospective interventional case series includes the treatment of naive patients with macular edema secondary to non-ischemic branch retinal vein occlusion who underwent intravitreal dexamethasone implantation. The patients were divided into two groups as follows: Group 1 (n=25), comprised of patients with macular edema secondary to branch retinal vein occlusion without epiretinal membrane, and Group 2 (n=16), comprised of patients with macular edema secondary to branch retinal vein occlusion with an epiretinal membrane. Corrected visual acuity, central macular thickness, and central macular volume values were measured before and after treatment. The clinical outcomes of the groups were compared.
Mean age and male-to-female ratio were similar between the two groups (p>0.05, for both). The baseline and final corrected visual acuity values, central macular thickness, and central macular volumes of the groups were similar (p>0.05, for all). All the parameters were significantly improved after intravitreal dexamethasone implantation treatment (p<0.001, for all). The changes in central macular thickness and volume were also similar (p>0.05, for both). The mean number of intravitreal dexamethasone implantations was 2.1 ± 1.0 (range, 1-4) in Group 1 and 3.0 ± 1.2 (range, 1-5) in Group 2 (p=0.043).
Epiretinal membrane formation had no effects on the baseline and final clinical parameters, including corrected visual acuity and central macular thickness and volume. The only parameter affected by the presence of epiretinal membrane formation is the number of intravitreal dexamethasone implantations, a greater number of which is needed for macular edema secondary to branch retinal vein occlusion with an epiretinal membrane.
探讨视网膜前膜形成对玻璃体内注射地塞米松植入治疗视网膜分支静脉阻塞继发黄斑水肿临床疗效的影响。
本回顾性干预性病例系列研究纳入了接受玻璃体内注射地塞米松植入治疗的初治视网膜分支静脉阻塞继发黄斑水肿患者。患者分为两组:第1组(n = 25),由无视网膜前膜的视网膜分支静脉阻塞继发黄斑水肿患者组成;第2组(n = 16),由有视网膜前膜的视网膜分支静脉阻塞继发黄斑水肿患者组成。在治疗前后测量矫正视力、中心黄斑厚度和中心黄斑体积值。比较两组的临床疗效。
两组的平均年龄和男女比例相似(两者p>0.05)。两组的基线和最终矫正视力值、中心黄斑厚度和中心黄斑体积相似(所有p>0.05)。玻璃体内注射地塞米松植入治疗后所有参数均显著改善(所有p<0.001)。中心黄斑厚度和体积的变化也相似(两者p>0.05)。第1组玻璃体内注射地塞米松的平均次数为2.1±1.0(范围1 - 4次),第2组为3.0±1.2(范围1 - 5次)(p = 0.043)。
视网膜前膜形成对包括矫正视力、中心黄斑厚度和体积在内的基线和最终临床参数无影响。受视网膜前膜形成影响的唯一参数是玻璃体内注射地塞米松的次数,对于有视网膜前膜的视网膜分支静脉阻塞继发黄斑水肿,需要更多次数的注射。